Table 1.

Characteristics of the study population and PFAS serum concentrations

	n	Median	25th-75th percentiles
Age (years)	109	12.6	11.5–13.2
Tanner stage	100
1	20
2	33
3	29
4	16
5	2
SES	108
1	57
2	20
3	36
4	5
5	0
Height (cm)	109	158.3	150.9–166.7
Height SDS	109	0.11	-0.65–0.87
Weight (kg)	109	44.9	38.6–51.5
Weight SDS	109	0.01	-0.73–0.75
BMI (kg/m2)	109	17.7	16.5–19.8
BMI SDS	109	0.30	-0.83–0.60
Body fat assessed by MRI (%)
Abdominal fat	109	18.9	16.5–24.8
Visceral fat	109	6.47	5.69–7.39
Body fat assessed by DXA (%)
Total body fat	108	16.8	12.8–24.8
Total body fat SDS	108	-0.08	-0.63–0.77
Android fat	108	16.3	11.6–26.7
Gynoid fat	108	26.7	22.2–35.8
Android/gynoid ratio	108	0.6	0.51–0.78
PFAS serum concentrations (ng/mL)
PFOA	109	2.79	2.18–3.58
PFOS	109	6.81	5.85–9.47
PFHxS	109	0.50	0.40–0.65
PFNA	109	0.92	0.73–1.17
PFDA	109	0.31	0.25–0.37

BMI Body mass index, SDS Standard deviation score, PFAS Perfluoroalkyl substances, PFOA Perfluorooctanoic acid, PFOS Perfluorooctane sulfonic acid, PFHxS Perfluorohexane sulfonic acid, PFNA Perfluorononanoic acid, PFDA Perfluorodecanoic acid, SES Socioeconomic status